Expression and clinical significance of heparanase in neuroblastoma
Expression and clinical significance of heparanase in neuroblastoma
复制标题
乙酰肝素酶在神经母细胞瘤中的表达及临床意义
DOI：
10.1007/s12519-009-0039-9
复制
发表时间：
2009-08
期刊：
影响因子：
--
通讯作者：
郑丽端
中科院分区：
文献类型：
--
作者：
郑丽端
研究背景乙酰肝素酶(heparanase，HPA)是一种参与肿瘤血管生成和转移的内切糖苷酶，在多种恶性肿瘤中表达上调。然而，神经母细胞瘤(NB)是儿童最常见的颅外实体肿瘤之一，其HPA的表达仍不清楚。方法采用免疫组织化学方法检测42例神经母细胞瘤中HPA的表达。结果42例神经母细胞瘤中HPA的阳性表达率为61.9%(26/42)，主要分布于神经母细胞瘤细胞胞浆。1-2期、3-4期和4S期的阳性表达率分别为35.7%、80.0%和62.5%。1-2期与3-4期之间差异有统计学意义(P<；0.01)。HPA在年龄大于1岁(P<；0.01)、分化较差(P<；0.01)、核分裂指数较高(P<；0.01)的Nb组织中的表达显著升高。HPA阴性患者的生存时间明显长于HPA阳性患者(P<；0.05)。结论虽然肝素酶可能与NB的发生发展有关，但可能需要更多的患者和更长的随访时间来加强其在评估NB预后中的作用。
BackgroundPrevious studies indicate that heparanase (HPA), an endoglycosidase involved in tumor angiogenesis and metastasis, is up-regulated in a variety of malignancies. However, the expression of HPA in neuroblastoma (NB), one of the most common extra cranial solid tumors in children, remains unknown. This study was undertaken to explore the expression and clinical significance of HPA in NB.MethodsImmunohistochemical staining was applied to detect the expression of HPA in 42 cases of NB. The relationships among HPA expression, international neuroblastoma staging system (INSS) stages, histopathological classification, and postoperative survival of the NB patients were analyzed.ResultsThe expression rate of HPA in NB was 61.9% (26/42), mainly in the cytoplasm of neuroblastoma cells. The expression rates of stage 1–2, stage 3—4 and stage 4S were 35.7%, 80.0% and 62.5%, respectively. The differences between stage 1–2 and stage 3–4 were significant (P<0.01). The expression of HPA was significantly higher in the NB cases that had one of the histopathological factors: age more than 1 year (P<0.01), poorer differentiation (P<0.01), and higher mitosis karyorrhexis index (P<0.01). The survival time of HPAnegative patients was significantly longer than that of HPA-positive patients (P<0.05).ConclusionAlthough these results indicate that heparanase might be correlated with development and progression of NB, a larger series of patients with a longer follow-up are probably needed to strengthen its role in assessment of NB prognosis.
登录
查看更多内容
影响因子：
6.4
作者：
Tetsuhiko Nomura;H. Hasegawa;Masashi Kohno;Miho Sasaki;S. Fujita
通讯作者：
Tetsuhiko Nomura;H. Hasegawa;Masashi Kohno;Miho Sasaki;S. Fujita
影响因子：
10.3
作者：
Edovitsky, E;Elkin, M;Vlodavsky, I
通讯作者：
Vlodavsky, I
影响因子：
5.7
作者：
Nobuhisa, Tetsuji;Naomoto, Yoshio;Tanaka, Noriaki
通讯作者：
Tanaka, Noriaki
影响因子：
8.7
作者：
Q. Tong;Li-duan Zheng;S. Tang;Qing-lan Ruan;Yuan Liu;Shi-wang Li;Guo-song Jiang;Jia-bin Cai
通讯作者：
Q. Tong;Li-duan Zheng;S. Tang;Qing-lan Ruan;Yuan Liu;Shi-wang Li;Guo-song Jiang;Jia-bin Cai
影响因子：
11.2
作者：
A. Zetser;Y. Bashenko;Evgeny Edovitsky;F. Levy-Adam;I. Vlodavsky;N. Ilan
通讯作者：
A. Zetser;Y. Bashenko;Evgeny Edovitsky;F. Levy-Adam;I. Vlodavsky;N. Ilan